Cargando…
Mastocytosis: One Word for Different Diseases
Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360005/ https://www.ncbi.nlm.nih.gov/pubmed/32700030 http://dx.doi.org/10.1007/s40487-018-0086-2 |
_version_ | 1783559151358574592 |
---|---|
author | Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio |
author_facet | Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio |
author_sort | Criscuolo, Marianna |
collection | PubMed |
description | Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia. |
format | Online Article Text |
id | pubmed-7360005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-73600052020-07-20 Mastocytosis: One Word for Different Diseases Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio Oncol Ther Review Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia. Springer Healthcare 2018-10-29 /pmc/articles/PMC7360005/ /pubmed/32700030 http://dx.doi.org/10.1007/s40487-018-0086-2 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio Mastocytosis: One Word for Different Diseases |
title | Mastocytosis: One Word for Different Diseases |
title_full | Mastocytosis: One Word for Different Diseases |
title_fullStr | Mastocytosis: One Word for Different Diseases |
title_full_unstemmed | Mastocytosis: One Word for Different Diseases |
title_short | Mastocytosis: One Word for Different Diseases |
title_sort | mastocytosis: one word for different diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360005/ https://www.ncbi.nlm.nih.gov/pubmed/32700030 http://dx.doi.org/10.1007/s40487-018-0086-2 |
work_keys_str_mv | AT criscuolomarianna mastocytosisonewordfordifferentdiseases AT fianchiluana mastocytosisonewordfordifferentdiseases AT maraglinoalessiome mastocytosisonewordfordifferentdiseases AT paganolivio mastocytosisonewordfordifferentdiseases |